A drug targeting mRNA essential for APO C-III production provided a 50% reduction in triglycerides in BRIDGE-TIMI 73a, the largest ever observed in a controlled trial.
The investigational agent significantly improved liver biomarkers of disease activity and symptoms of pruritus in adults with PBC enrolled in a phase 3 trial.
Between 25% and 58% of Americans have a fatty liver disease— a dietitian shares her expert recommends for to eat and avoid if you want to maintain liver health.